Seventure Partners
Seventure Partners is a Paris-based European venture capital firm founded in 1997, managing ~€1 billion in AUM across Life Sciences and Digital Technologies. A Natixis Investment Managers subsidiary (Groupe BPCE), it operates thematic funds in microbiome, sport, blue economy, and digital innovation.
- Company typePrivate
- Founded1997
- HeadquartersParis, France
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Seventure Partners does
Seventure Partners is a Paris-headquartered European venture capital firm founded in 1997 and operating as a wholly owned subsidiary of Natixis Investment Managers, which in turn sits within Groupe BPCE, a major French banking group. The firm invests across two principal franchises — Life Sciences and Digital Technologies — and manages approximately €1 billion in assets under management as of June 30, 2024. Seventure is staffed by 20+ employees including 26 investment professionals (10 of whom are Venture Partners) and maintains offices in Paris, Munich, London, Geneva, and Basel, with investment activity spanning Europe, North America, Israel, and Asia. As a regulated French portfolio management company (AMF approval GP 01-040), the firm operates on a Limited Partnership model with capital pooled across multiple thematic fund vehicles.
The firm runs a multi-vehicle thematic platform rather than a single diversified fund. The Life Sciences franchise is anchored by the Health for Life Capital™ vehicles (HFLI at €160M, HFLII targeting €200M+, oversubscribed at time of disclosure) — described as the first European vehicles dedicated to financing the microbiome revolution in health and nutrition, backed by strategic LPs including Danone, Novartis, Bel, Lesaffre, Adisseo, and Tereos. Digital Technologies exposure is delivered through the Digital Opportunities Fund, the Sport & Performance Capital vehicle (~€80M, launched with Caisse d'Epargne as Premium Partner of the Paris 2024 Olympics), the Blue Forward Fund (blue economy, SFDR Article 9), AVF (animal health and AgTech, backed by Adisseo), the Quadrivium 1 seed fund (€56.1M with 12 French academic partners including UPMC, CNRS, and Institut Curie), and retail FCPI vehicles (Vie Numérique & Santé 2022-2023 and 2024-2025) that offer French individual investors a 20% income tax reduction. Portfolio scale spans 150+ historical exits including AAA (sold to Novartis for $3.9B) and Santaris (sold to Roche for $250-450M).
The business model rests on three revenue streams: (1) recurring fund management fees, typically 2% of committed and deployed capital across the firm's multiple fund vehicles; (2) carried interest on fund returns above preferred-return hurdles, evidenced by the historical SPEF Pre-IPO fund's 31% reported IRR; and (3) capital gains on direct balance-sheet co-investments. Seventure's LP base is concentrated among strategic corporates and institutional partners, the firm's tickets range from €1-5M per round (digital) to €1-10M initial tickets with up to €20M follow-on capacity per company (life sciences), and the firm holds UNPRI signatory status (2016), France Invest Charter membership (2017), and SFDR Article 8/9 classifications across multiple funds.
Seventure Partners firmographics
Firmographics- Name
- Seventure Partners
- Legal name
- Seventure Partners (Société anonyme à Directoire et Conseil de Surveillance)
- Website
- https://seventure.fr
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Seventure Partners is a Paris-based European venture capital firm founded in 1997, managing ~€1 billion in AUM across Life Sciences and Digital Technologies. A Natixis Investment Managers subsidiary (Groupe BPCE), it operates thematic funds in microbiome, sport, blue economy, and digital innovation.
- Ownership category
- akta.pro rank
Seventure Partners industry classification
Industry- Product category
- Venture Capital and Private Equity Fund Management
- NAICS
- Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394), Other Financial Investment Activities (5239)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
Keywords
Where Seventure Partners is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Markets served
Seventure Partners business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Others, Technology or R&D
Revenue model
- Fund management fees: Recurring management fees charged on committed and deployed capital across the firm's multiple fund vehicles (Health for Life Capital I & II, Digital Opportunities Fund, Quadrivium 1, Sport & Performance Capital, etc.) — typical 2% annual management fee on committed/invested capital.
- Carried interest (performance fees): Performance-based carried interest on fund returns above preferred return hurdles (historical SPEF Pre-IPO fund reported 31% IRR). Sourced from successful exits and IPOs across the 150+ exit portfolio.
- Capital gains on direct balance-sheet investments: Realized and unrealized gains from the firm's balance-sheet co-investments alongside fund vehicles and historical exits (e.g., Santaris sold to Roche for $250-450M, AAA sold to Novartis for $3.9B, Conject sold to Aconex for €65M).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Digital Technologies investment tickets |
| Other | Multi-year contract | Life Sciences investment tickets |
| One time/ perpetual license | Multi-year contract | Retail investor access via FCPI vehicle |
Go-to-market motion1 record
Seventure Partners product offering
Product offeringCore offering
Seventure Partners is a European venture capital firm that manages multiple thematic funds investing in early-to-growth stage companies across two principal franchises: Life Sciences (microbiome, nutrition, health, medical devices, animal health) and Digital Technologies (fintech, retailtech, sportech, blue economy). Capital is deployed through institutional vehicles (Health for Life Capital™, Digital Opportunities Fund, Sport & Performance Capital™, Blue Forward Fund™, AVF, Quadrivium 1) and retail FCPI products, with typical tickets of €1–10M per round and follow-on capacity up to €10–20M per company. The firm is AMF-approved (GP 01-040) and operates as a wholly owned subsidiary of Natixis Investment Managers.
Product overview
Seventure Partners is a European venture capital firm (founded 1997, €1bn under management as of 30 June 2024) that operates a multi-fund platform for financing innovative growth companies in two principal domains — Life Sciences and Digital Technologies — plus dedicated thematic franchises for sport, blue economy, animal health and academic seed. The platform is anchored by thematic institutional funds including Health for Life Capital™ (microbiome in health and nutrition, with strategic LPs Danone, Novartis, Bel, Tereos, Tornier, Lesaffre), Digital Opportunities Fund (fintech, retailtech, and other digital innovations in France and Germany), Sport & Performance Capital (~€80M sport economy and well-being fund launched with Caisse d'Epargne), Blue Forward Fund (blue economy), AVF (animal health, feed, nutrition and AgTech, backed by Adisseo), and Fonds d'Amorçage Quadrivium 1 (€56.1M seed fund for French academic spinouts). These institutional vehicles are complemented by retail products such as the Vie Numérique & Santé 2022-2023 FCPI, which provides individual investors a 20% income tax reduction in exchange for investment in digital and life sciences innovation. Seventure Partners is a subsidiary of Natixis Investment Managers and is approved by the French AMF (Autorité des Marchés Financiers) under number GP 01-040.
Differentiator
Problem solved
Functional benefit
Brands
- Health for Life Capital™: Venture fund dedicated to health, life sciences, nutrition, and digital health investments.
- Sport & Performance Capital™
- Blue Forward Fund™
- Digital Opportunities
- Quadrivium
- AVF
Products and services
- Health for Life Capital™ European investment vehicles (Health for Life Capital™ I at €160M and Health for Life Capital™ II targeting €200M+) investing in microbiome innovation in health and nutrition, with strategic LPs including Danone, Novartis, Bel, Tereos, Tornier, and Lesaffre. First European vehicles dedicated to financing the microbiome revolution in health and nutrition. Targets Seed to Series C investments with initial ticket sizes of €1-10M and follow-on capacity up to €20M per company.
- Digital Opportunities Fund
- Sport & Performance Capital™ Thematic institutional venture fund of approximately €80M targeting the French sport and well-being economy, investing in sport-health, equipment, nutrition, IoT-digital, and sport practice innovations. Launched with the support of Caisse d'Epargne. Classified under SFDR Article 8.
- Blue Forward Fund™ Institutional venture capital fund focused on the Blue Economy sectors including sustainable aquaculture, nutrition-cosmetic-health, industrial products and biomaterials, biopolymers and biopackaging, blue digitalization, recycling, climate and carbon, and bioenergies/hydrogen. Classified under SFDR Article 9.
- AVF Seventure-affiliated venture fund brand focused on animal health, feed, nutrition and AgTech, backed by Adisseo as a strategic LP.
- Fonds d'Amorçage Quadrivium 1 €56.1M seed fund created in November 2013 for French seed-stage companies linked to 12 academic and university partners in digital technologies and life sciences (excluding microbiome).
- Vie Numérique & Santé 2022-2023 FCPI French FCPI (Fonds Commun de Placement dans l'Innovation) vehicle available to individual French tax-resident investors, offering a 20% income tax reduction in exchange for investment in innovative companies in digital technologies and life sciences (health, food, work, security, mobility, habitat). Subscriber funds are locked until at least 31 December 2030. Classified under SFDR Article 8.
Companies that use Seventure Partners
Customer profileIdeal customer profiles3 records
Seventure Partners technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Seventure Partners partnerships and signals
Strategic signalRecent moves10 records
Expansion highlights6 records
Seventure Partners competitors and assessment
Company assessmentDirect peers
- Andera Partners: Paris-based private equity and venture capital firm (formerly Edmond de Rothschild Investment Partners) with dedicated life sciences (Andera Life Sciences / BioDiscovery) and digital growth strategies; comparable to Seventure as a French-anchored multi-thematic platform.
- Gilde Healthcare: European healthcare-focused venture and growth capital firm (Utrecht, Netherlands) investing in medtech, digital health, therapeutics and specialty care; direct competitor in the European life sciences/healthtech VC space where Seventure's HFL franchise operates.
- Cathay Capital: Paris- and Singapore-based cross-border venture and growth capital firm investing in digital technologies and healthcare between Europe, North America and Asia; comparable to Seventure in its pan-European/Asian orientation and dual digital/life-sciences thesis.
- Sofinnova Partners: Paris-based European venture capital firm investing across life sciences (biopharma, medtech, digital health) and digital/industrial; the closest French-anchored peer to Seventure with overlapping Life Sciences and Digital mandates and similar ticket sizes.
- Index Ventures: London- and San Francisco-based venture capital firm investing across technology and life sciences; comparable to Seventure's Digital Opportunities franchise in stage, ticket size and pan-European digital deal flow.
- Balderton Capital: London-based early-stage venture capital firm investing in European technology startups from Seed to Series A; directly comparable to Seventure's Digital Opportunities Fund in stage focus and pan-European digital-tech thesis.
- Forbion: European life sciences venture capital firm (Naarden, Netherlands) investing Seed to Series C in biopharma and medical devices; directly comparable to Seventure's Health for Life Capital franchise in stage focus, sector specialization and European footprint.
Broad incumbents
- Bpifrance: France's public investment bank, a major French VC and growth investor across digital and life sciences; broader incumbent that co-invests alongside Seventure (e.g., ErVimmune, Karmen) and competes for the same French innovation pipeline.
- Eurazeo: Paris-headquartered European investment firm with private equity, venture and growth strategies including a healthcare-focused franchise; comparable as a large French-anchored multi-thematic investor, though operating at a significantly larger scale than Seventure.
- EQT Ventures: Stockholm-headquartered EQT's venture arm, investing across European digital and life sciences themes at Seed to Growth; broader incumbent comparable to Seventure's full multi-fund platform, though operating at materially larger fund sizes and ticket levels.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Seventure Partners social profiles
Digital presenceSeventure Partners compliance and trust
Trust signalCompliance7 records
Seventure Partners financial estimates
Financial estimateRevenue estimate
Valuation estimate
Seventure Partners leadership team
Management profileNumber of profiles
Profiles7 records
Seventure Partners funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Seventure Partners M&A and investment
M&A and investmentM&A
Investments309 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Seventure Partners
What does Seventure Partners do?
Seventure Partners is a European venture capital firm that manages multiple thematic funds investing in early-to-growth stage companies across two principal franchises: Life Sciences (microbiome, nutrition, health, medical devices, animal health) and Digital Technologies (fintech, retailtech, sportech, blue economy). Capital is deployed through institutional vehicles (Health for Life Capital™, Digital Opportunities Fund, Sport & Performance Capital™, Blue Forward Fund™, AVF, Quadrivium 1) and retail FCPI products, with typical tickets of €1–10M per round and follow-on capacity up to €10–20M per company. The firm is AMF-approved (GP 01-040) and operates as a wholly owned subsidiary of Natixis Investment Managers.
Is Seventure Partners a public or private company?
Seventure Partners is a private company. It is classified as corporate owned and is currently operating.
When was Seventure Partners founded?
Seventure Partners was founded in 1997. It employs 11 to 50 people.
Where is Seventure Partners based?
Seventure Partners is headquartered in Paris, France, in the Europe region.
How does Seventure Partners make money?
Three revenue lines are on record. Fund management fees are the primary driver. The others are carried interest (performance fees) and capital gains on direct balance-sheet investments.
Who are Seventure Partners's main competitors?
Direct peers on record are Andera Partners, Gilde Healthcare, Cathay Capital, Sofinnova Partners, Index Ventures, Balderton Capital and Forbion. Broad incumbents are Bpifrance, Eurazeo and EQT Ventures.
Does Seventure Partners have an API?
No public API is recorded for Seventure Partners.
What industry is Seventure Partners in?
Seventure Partners's product category is Venture Capital and Private Equity Fund Management. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 523940 and its SIC code is 6282.